On March 15, 2023 Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos Bioventures, "Sporos" or the "Company"), a precision oncology company developing a diversified pipeline of small molecule therapeutic programs targeting cancer vulnerabilities in the tumor and tumor microenvironment, reported that it will present a poster highlighting preclinical data from the company’s novel, isoform selective TEAD inhibitor, SPR1, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 taking place April 14-19, 2023, in Orlando, FL (Press release, Sporos Bioventures, MAR 15, 2023, View Source [SID1234628798]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to presenting preclinical data on our TEAD inhibitor, which we believe has best-in-class potential based on its optimized TEAD isoform selectivity profile and resultant preclinical activity superior to that of other compounds in development," said Stephen Rubino, Ph.D., Sporos’ Chief Executive Officer. "SPR1 inhibitors show single-agent activity against multiple TEAD-dependent cell lines in vitro and in vivo, including a range of non-NF2 mutation cell lines and those cell lines that are simply YAP-hyperactive. In addition, our differentiated TEAD inhibitors have demonstrated potent synergistic activity in combination with inhibitors of the MAPK pathway, creating the potential for broad applicability across a number of cancers with serious unmet medical need."
Presentation Details:
Title: A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy
Session Category: Experimental and Molecular Therapeutics
Session Title: New Drug Targets
Session Date and Time: Sunday Apr 16, 2023, 1:30 PM – 5:00 PM
Abstract Number: 445